New vaccine combo shows promise in ovarian cancer fight
NCT ID NCT03029403
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests whether combining a cancer vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine trains the immune system to attack cancer cells, while pembrolizumab helps the immune system stay active. The study includes 47 participants whose cancer has returned after prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.